Cardiac Critical Care — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cardiac critical care (cardiac intensive care unit, or CICU) is a specialised form of intensive care medicine dedicated to the monitoring and management of patients with life-threatening cardiac conditions. The CICU combines the diagnostic expertise of cardiology with the physiological monitoring, organ support capabilities, and nursing intensity of critical care medicine. It is distinct from general medical or surgical ICUs in that the team possesses specific expertise in haemodynamic monitoring, mechanical circulatory support, complex arrhythmia management, and post-cardiac interventional care.

Modern CICUs are equipped with continuous multi-parameter monitoring — including invasive arterial blood pressure, central venous pressure, pulmonary artery catheter-derived haemodynamics, cardiac output monitoring, pulse oximetry, and bedside echocardiography — enabling rapid identification of haemodynamic deterioration and immediate therapeutic response. Advanced monitoring tools including the PiCCO system, FloTrac, and point-of-care ultrasound have transformed the ability to assess cardiac function and fluid responsiveness at the bedside without invasive catheterisation.

The typical patient journey through the CICU begins at the point of emergency admission with a life-threatening cardiac event — most commonly acute myocardial infarction complicated by haemodynamic compromise, acute decompensated heart failure, or post-operative recovery after cardiac surgery. A rapid systematic assessment of haemodynamics, coronary anatomy (via urgent catheterisation), and organ perfusion guides immediate management decisions. Multidisciplinary rounds involving intensivists, cardiologists, cardiac surgeons, pharmacists, and nurses occur at least twice daily, with continuous nursing assessment throughout.

Cardiogenic shock — the most severe form of acute heart failure, defined as systolic blood pressure below 90 mmHg with signs of tissue hypoperfusion (cold peripheries, oliguria, elevated lactate) due to primary cardiac dysfunction — accounts for approximately 5–10% of acute myocardial infarction presentations and carries a 30-day mortality of 40–50% despite optimal therapy. CICU care combines emergent revascularisation (primary PCI), vasopressor and inotropic support, and — in selected patients — mechanical circulatory support devices including the intra-aortic balloon pump, Impella, and extracorporeal membrane oxygenation (ECMO).

Other conditions managed in cardiac critical care include acute decompensated heart failure (refractory pulmonary oedema requiring non-invasive ventilation, high-dose intravenous diuresis, or vasodilator therapy), acute right ventricular failure (from massive pulmonary embolism or right ventricular infarction), life-threatening cardiac arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, complete heart block), hypertensive emergencies causing end-organ damage, acute aortic dissection requiring blood pressure control and urgent surgical planning, and post-cardiac surgery care including management of low cardiac output state, coagulopathy, and mechanical complications.

CICU admission is indicated for any patient with haemodynamic instability attributable to a cardiac cause — including cardiogenic shock, acute decompensated heart failure with respiratory failure, life-threatening arrhythmias requiring antiarrhythmic infusion or repeated cardioversion, acute myocardial infarction with complications, and all patients immediately following major cardiac surgical procedures. Patients are also admitted following high-risk cardiac interventional procedures (complex PCI, transcatheter valve implantation, electrophysiology ablation for ventricular arrhythmias) requiring intensive monitoring in the immediate post-procedural period.

The CICU is not appropriate for patients with an established prognosis limiting expected benefit — for example, patients with metastatic cancer and cardiac complications, or patients who have clearly expressed a preference to avoid invasive interventions in a valid advance directive. Goals of care discussions involving the patient, family, and the CICU team are an integral part of CICU care, particularly when the prognosis is poor or when escalation of support (mechanical ventilation, renal replacement therapy, ECMO) is being considered. Withdrawing or withholding life-sustaining treatment when it is no longer beneficial is a recognised and ethically appropriate component of CICU care.

Haemodynamic support in cardiogenic shock uses vasopressors (noradrenaline, vasopressin) to maintain systemic blood pressure and perfusion pressure, and inotropes (dobutamine, milrinone, levosimendan) to improve cardiac contractility and output, though all inotropes increase myocardial oxygen demand and arrhythmia risk. Mechanical circulatory support devices are used when pharmacological support is insufficient: the intra-aortic balloon pump (IABP) reduces afterload and augments diastolic pressure (improving coronary perfusion) by counter-pulsation but has limited ability to augment cardiac output; the Impella device (a micro-axial flow pump inserted across the aortic valve) can provide up to 5.5 litres of additional cardiac output per minute; and veno-arterial ECMO (VA-ECMO) provides full cardiopulmonary bypass support for the most refractory cases.

Respiratory support in acute decompensated heart failure progresses from high-flow nasal oxygen to non-invasive ventilation (CPAP or BiPAP — which rapidly reduces respiratory work and improves pulmonary oedema in acute left ventricular failure, avoiding intubation in 60–70% of cases) and endotracheal intubation with mechanical ventilation for refractory respiratory failure. Renal replacement therapy (continuous veno-venous haemofiltration, CVVH) addresses the cardiorenal syndrome — worsening renal function in the context of heart failure — allowing fluid removal, correction of metabolic acidosis, and clearance of uraemic toxins when loop diuretics are insufficient. Targeted temperature management (TTM) at 33–36°C for 24 hours following cardiac arrest with return of spontaneous circulation reduces neurological injury. Continuous renal replacement therapy (CRRT) manages fluid overload, correction of metabolic acidosis, and clearance of uraemic toxins when loop diuretics are insufficient.

Cardiac critical care has transformed survival from previously almost universally fatal acute cardiac conditions. Early mechanical revascularisation in cardiogenic shock complicating myocardial infarction improves 6-month survival from 13% with medical therapy alone to 51% — establishing primary PCI combined with CICU management as the standard of care (SHOCK trial). Advanced mechanical circulatory support including ECMO has enabled survival in patients with otherwise refractory cardiac failure, with 30-day survival in out-of-hospital cardiac arrest patients treated with extracorporeal cardiopulmonary resuscitation (ECPR) exceeding 30–40% at experienced centres.

For acute decompensated heart failure, evidence-based CICU protocols combining high-dose loop diuresis, vasodilators (intravenous nitrates, sodium nitroprusside), and early non-invasive ventilation result in in-hospital mortality below 5% for most patients and allow 80–90% of patients to be discharged alive. Post-cardiac surgery CICU care, combining meticulous haemodynamic management, early extubation protocols (fast-track cardiac anaesthesia), and aggressive cardiac rehabilitation, has reduced post-CABG in-hospital mortality to below 2% at high-volume centres.

CICU admission itself carries risks associated with the invasive monitoring and devices required for critically ill cardiac patients. Central venous catheter insertion (for vasopressor administration and CVP monitoring) carries risks of pneumothorax (1–2%), arterial puncture, and central line-associated bloodstream infection (CLABSI) — the last of which is mitigated by strict sterile insertion and maintenance protocols. Pulmonary artery catheter insertion carries risks of pulmonary artery rupture (rare but catastrophic), arrhythmia induction, and knotting.

Mechanical circulatory support devices carry specific complications: IABP can cause limb ischaemia, thrombocytopenia, and aortic injury (rare); Impella devices are associated with haemolysis, limb ischaemia from the femoral access site, and device malposition; VA-ECMO carries high rates of bleeding (20–40%), lower limb ischaemia (10–20%), thrombosis, neurological complications (stroke in 5–8%), and ECMO circuit infections. Prolonged ICU stay is associated with ICU-acquired weakness (muscle wasting and weakness from immobility, inflammation, and corticosteroid use), delirium (affecting up to 80% of mechanically ventilated patients and associated with long-term cognitive impairment), and hospital-acquired infections.

Recovery from cardiac critical illness is a prolonged process extending well beyond CICU discharge. Patients typically step down from the CICU to a high-dependency cardiac unit for continued monitoring and progressive rehabilitation before general ward transfer. The ICU-to-ward transition is a vulnerable period requiring careful communication and handover. Cardiac rehabilitation is initiated as soon as haemodynamic stability allows — beginning with passive limb movements and progressing to active exercises, progressing in intensity over weeks to months.

Long-term follow-up in survivors of cardiogenic shock, cardiac arrest, or acute myocardial infarction with reduced ejection fraction focuses on optimisation of guideline-directed medical therapy for heart failure (ACE inhibitor/ARB/sacubitril-valsartan, beta-blocker, mineralocorticoid receptor antagonist, SGLT2 inhibitor), assessment of implantable cardioverter-defibrillator (ICD) candidacy, cardiac rehabilitation programme completion, and psychosocial support — including screening and management of post-traumatic stress disorder (PTSD), which affects 10–20% of CICU survivors. Repeat echocardiography at 90 days guides decisions on ICD implantation and advanced heart failure therapies.

CICU care is among the most expensive in modern medicine, reflecting the intensity of nursing, specialist monitoring, and high-cost devices. In the United States, a single day of cardiac ICU care costs approximately $5,000–$10,000; ECMO support adds $2,000–$3,000 per day in circuit consumables and specialist staffing. A 2-week CICU admission can easily cost $100,000–$200,000 or more. In the UK, NHS CICU care is provided free at the point of care, with equivalent private care costing £2,000–£5,000 per day.

For international patients requiring elective post-cardiac surgery CICU monitoring (such as those travelling for CABG or valve replacement surgery at overseas centres), India, Thailand, and Turkey offer world-class cardiac surgery with integrated CICU care at 60–80% lower total cost than equivalent care in the United States or United Kingdom. Post-operative CICU care is included within the all-inclusive cardiac surgery packages offered by leading international cardiac centres. For acute life-threatening cardiac emergencies, care must be sought at the nearest available cardiac centre regardless of cost considerations.

For patients at risk of haemodynamic deterioration following acute cardiac events, high-dependency unit (HDU) monitoring — a step-down environment with enhanced nurse-to-patient ratios and continuous cardiac monitoring but fewer invasive devices than full ICU care — may be appropriate for less critically ill patients, freeing full CICU beds for the most unstable cases. Cardiogenic shock prediction scores (such as the IABP-SHOCK II risk score) help identify patients who are likely to deteriorate and require proactive CICU-level support rather than reactive escalation.

For patients with chronic advanced heart failure who are unsuitable for cardiac transplantation or who are awaiting it, destination therapy with an implantable left ventricular assist device (LVAD) — such as the HeartMate 3 — represents an alternative to repeated CICU admissions for acute decompensation, improving quality of life and 2-year survival in appropriately selected patients. Palliative and supportive care is an important alternative pathway for patients with refractory end-stage cardiac failure who decline or are not candidates for aggressive CICU-level intervention.